Cart
sales@molnova.com
SLC13A5-IN-1
CAS No. 2227548-95-8
SLC13A5-IN-1( —— )
Catalog No. M26450 CAS No. 2227548-95-8
SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks?the uptake of?14C-citrate(IC50 : 0.022 μM in HepG2 cells).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 88 | Get Quote |
|
| 10MG | 147 | Get Quote |
|
| 25MG | 267 | Get Quote |
|
| 50MG | 447 | Get Quote |
|
| 100MG | 624 | Get Quote |
|
| 200MG | 884 | Get Quote |
|
| 500MG | 1305 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSLC13A5-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionSLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks?the uptake of?14C-citrate(IC50 : 0.022 μM in HepG2 cells).
-
DescriptionSLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks?the uptake of?14C-citrate(IC50 : 0.022 μM in HepG2 cells).(In Vitro):In HepG2/14C-Citrate Uptake Assay，SLC13A5-IN-1 exhibits an IC50 of 0.022 μM . HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate.In recombinant hSLC3A5/14C-Citrate Uptake Assay, SLC13A5-IN-1 exhibits an IC50 of 0.056 μM . SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.
-
In VitroSLC13A5-IN-1 exhibits an IC50 of 0.022 μM in HepG2/14C-Citrate Uptake Assay. HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate. T.SLC13A5-IN-1 exhibits an IC50 of 0.056 μM in recombinant hSLC3A5/14C-Citrate Uptake Assay.SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetSCD
-
Recptordopamine uptake
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2227548-95-8
-
Formula Weight461.78
-
Molecular FormulaC19H19Cl3N2O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (27.07 mM)
-
SMILESClc1ccc(CNC(=O)C2CCN(CC2)S(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.CHEN JY. Pharmacologic properties of tropine 4-chlorobenzhydryl ether hydrochloride (SL-6057), a potent long-acting antihistaminic agent. J Pharmacol Exp Ther. 1955 Jun;114(2):192-202.
molnova catalog
related products
-
SLC13A5-IN-1
SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks?the uptake of?14C-citrate(IC50 : 0.022 μM in HepG2 cells).
-
SCD1 inhibitor-1
SCD1 inhibitor-1 is a potent and liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitor.
-
CVT-12012
CVT-12012 is an orally bioavailable inhibitor of stearoyl-CoA desaturase (SCD; IC50 = 6.1 nM in HepG2 cells).
